|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-7-4
|
|
pubmed:abstractText |
Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV). However, the role of these polymorphisms in protecting injection drug users who are at high risk for HCV infection but do not have detectable antibodies against HCV or HCV RNA (exposed uninfected) has not been demonstrated. We investigated whether these individuals have the IL28B genotype rs12979860-CC, which protects some individuals against HCV infection.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/HLA-C Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis C Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/IL28B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukins,
http://linkedlifedata.com/resource/pubmed/chemical/KIR2DL3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, KIR2DL3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
141
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
320-5, 325.e1-2
|
|
pubmed:dateRevised |
2011-10-31
|
|
pubmed:meshHeading |
pubmed-meshheading:21600205-Adult,
pubmed-meshheading:21600205-Disease Progression,
pubmed-meshheading:21600205-Female,
pubmed-meshheading:21600205-Gene Frequency,
pubmed-meshheading:21600205-Genetic Predisposition to Disease,
pubmed-meshheading:21600205-Great Britain,
pubmed-meshheading:21600205-HLA-C Antigens,
pubmed-meshheading:21600205-Hepacivirus,
pubmed-meshheading:21600205-Hepatitis C,
pubmed-meshheading:21600205-Hepatitis C, Chronic,
pubmed-meshheading:21600205-Hepatitis C Antibodies,
pubmed-meshheading:21600205-Humans,
pubmed-meshheading:21600205-Immunity, Innate,
pubmed-meshheading:21600205-Interleukins,
pubmed-meshheading:21600205-Logistic Models,
pubmed-meshheading:21600205-Male,
pubmed-meshheading:21600205-Middle Aged,
pubmed-meshheading:21600205-Odds Ratio,
pubmed-meshheading:21600205-Phenotype,
pubmed-meshheading:21600205-Polymorphism, Single Nucleotide,
pubmed-meshheading:21600205-RNA, Viral,
pubmed-meshheading:21600205-Receptors, KIR2DL3,
pubmed-meshheading:21600205-Remission, Spontaneous,
pubmed-meshheading:21600205-Risk Assessment,
pubmed-meshheading:21600205-Risk Factors,
pubmed-meshheading:21600205-Substance Abuse, Intravenous,
pubmed-meshheading:21600205-Viral Load
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection.
|
|
pubmed:affiliation |
Department of Hepatology, Division of Medicine, Imperial College London, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
